Imagine a doctor having a super-assistant that can read thousands of medical images and handwritten notes at once to spot patterns humans might miss. It's like having a master detective who connects clues from different files to figure out exactly how to treat a patient. This helps get the right treatment to the right person much faster and more accurately.
Prostate and kidney cancer management is often inadequate due to the inability of clinicians to effectively process vast amounts of unstructured multimodal data, leading to high costs and poor patient outcomes.
Multimodal AI decision support systems that integrate medical imaging, unstructured text notes, and biomarkers for cancer diagnosis and prognosis.
If you are an AI Diagnostics Developer dealing with the difficulty of combining image data with text notes — this project developed multimodal AI models that integrate imaging and clinical records to improve cancer diagnosis accuracy.
If you are a Private Oncology Clinic dealing with high costs of inadequate cancer management — this project developed a decision support system that improves patient stratification to reduce unnecessary procedures.
If you are a Precision Medicine Firm dealing with imprecise patient grouping for clinical trials — this project developed tools for better patient stratification in prostate and kidney cancers.
Based on available project data, specific pricing or implementation costs for the AI tools are not provided.
Yes, the project includes a large multinational clinical study across multiple hospitals to validate the models in real-world clinical settings.
Based on available project data, the project follows an open science approach, though specific licensing terms for commercial use are not detailed.
The system is designed as a decision support tool that analyzes medical imaging and unstructured clinical notes already present in electronic medical records.
The project period runs from 2023-04-01 to 2027-03-31, suggesting the tools will be refined and validated through early 2027.
The consortium is heavily weighted toward academic and research institutions (9 universities and 1 research center), but maintains a 17% industry ratio with 3 SMEs. This balance suggests a strong theoretical foundation with a clear path toward commercialization, supported by partners across 7 European countries.
Contact the Klinikum der Technischen Universität München (TUM Klinikum) for partnership inquiries.
Contact SciTransfer to connect with the COMFORT consortium for licensing or pilot opportunities.
